ABSTRACT
Small intestinal adenocarcinoma are rare tumors, accounting for only 3% of all gastrointestinal tumors. 1 It was estimated that, in 2016, there would be 10,090 new cases and 1,330 deaths from the disease in the United States. 1 The majority of patients with small intestinal adenocarcinoma present with advanced disease with limited treatment options. Platinum-based combination chemotherapy with 5-flourouracil is the most common chemotherapeutic regimen used in small bowel tumors, with only modest survival benefit. These tumors have a dismal prognosis, with a five-year overall survival rate of only 30%. 2 Thus, there is a strong need to explore new therapeutic strategies, including immunotherapy, in these rare tumors.
The programmed death 1 (PD-1) pathway is upregulated in the immune microenvironment of many cancers. 3 Immune checkpoint inhibitors directed against the PD-1/PD-L1 pathway have demonstrated durable tumor responses in patients with various malignancies including melanoma, lung cancer, and kidney cancer. 4 However, unselected colorectal cancers seem to be refractory to the immune blockade therapy. 4 Therefore, it is crucial to identify patient populations who will likely benefit from checkpoint blockade therapy.
PD-L1 expression on tumor-infiltrating immune cells and tumor cells is a marker of response and clinical benefit to immune checkpoint blockade using anti-PD-1 and anti-PD-L1 agents. 3 Although PD-L1 expression has been noted in several tumors, it varies significantly by tumor type. It appears most abundant in melanoma, lung cancer, and renal cancer, with poor expression in colorectal cancers, thus correlating with poor clinical benefit in © American Society for Clinical Pathology AJCP / Original article colorectal cancers in general. 4 However, recently Le et al reported a selective efficacy of anti PD-1/PD-L1 therapy in patients with microsatellite instability-high (MSI-H) colon cancers. 5 The frequency of MSI-H tumors in small intestinal adenocarcinomas is variable. Approximately 5% to 35% of all small intestinal adenocarcinomas were noted to have defects in the DNA mismatch repair proteins (MSI-H tumors). 6, 15, 16 MSI-H tumors in general have high tumor lymphocytic infiltration and activation relative to microsatellite stable (MSS) tumors. 7 However, the expression patterns of PD-1 and PD-L1 in the immune microenvironment and their relation to MSI status in small intestinal adenocarcinomas are not known.
The purpose of the present study is to explore the immune microenvironment, including infiltrating immune cell subsets as well as the expression of PD-1 and PD-L1 by immune cells and by tumor cells of small intestinal adenocarcinoma using immunohistochemistry (IHC).
Materials and Methods
From our departmental pathology archives, 42 small intestinal adenocarcinomas were identified from 41 patients (26 from Vanderbilt University Medical Center and 16 from the University of Rochester Medical Center) between January 1, 2000 and Septembre 1, 2015, with blocks available for IHC studies. Patient electronic medical records, pathology reports, and pathology slides were reviewed for demographics, clinical history, and pathologic features. This study was approved by the internal review boards at both Vanderbilt University and the University of Rochester.
For IHC, 4-μm unstained tumor sections from formalin-fixed paraffin-embedded tissue blocks were first deparaffinized by routine methods. After antigen retrieval, the sections were stained with primary antibodies, followed by antibody localization using the Dako Envision + HRP-labeled polymer (Dako, Carpinteria, CA). Staining was visualized by 5-minute incubation with diaminobenzidine. Details of the primary antibodies used in the study are listed in ❚Table 1❚.
Fourteen cases had known MSI status determined by a PCR-based MSI assay. The remaining 28 tumors were tested for DNA mismatch repair deficiency (MMR-D) by IHC staining for MLH1, MSH2, MSH6, and PMS2. Loss of expression of one or more of the proteins was considered evidence of an MSI-H phenotype. All tumors were stained for CD3, CD4, CD8, PD-1, and PD-L1, and 26 tumors were stained for CD20. For evaluation of CD3+ T cells, the stained slides were first reviewed at low-power fields (x4 objective), and the area of greatest positivity (excluding lymphoid aggregates) was selected for photographing and printing; this area was always located along the invasive front. CD3+ cells were counted manually in two high-power fields (hpf) per tumor. The same areas were used for manual counting of CD4+ and CD8+ cells under two hpf.
Cell surface expression of PD-L1 was evaluated on tumor cells and tumor-infiltrating immune cells, including tumor-infiltrating lymphocytes and histiocytes. Percentage of PD-L1-positive tumor cells in total tumor cells was estimated. For tumor cells, the IHC score was 0, 1, 2, or 3 if less than 1%, from 1% to 10%, from 11% to 50%, or greater than 50% of the tumor cells were positive, respectively. For tumor-infiltrating immune cells, percentage of the tumors' cross-sectional area occupied by PD-L1 expressing immune cells was assessed. The IHC score was 0, 1, 2, or 3 if less than 1%, between 1% and 5%, from 5% to less than 10%, or 10% and higher of the area occupied with PD-L1 expressing immune cells, respectively. In addition, the intensity of PD-L1 expression was scored as negative, weak, moderate, or strong. PD-1 expression was assessed on tumor-infiltrating immune cells. The percentage of PD-1 expressing immune cells was estimated. The intensity of PD-1 stain was also scaled as: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). The IHC score was 
Results

Clinicopathologic Features
Forty-two small bowel adenocarcinomas were identified from 41 patients, including 19 females and 22 males, with age ranging from 23 to 92 years. One of the patients had 2 metachronous primary tumors diagnosed 17 months apart. The duodenum was the most common primary site of tumor (22/44, 50%). Based on the American Joint Committee on Cancer (AJCC) 7th edition staging system for small intestinal adenocarcinoma, 8 there were one stage I, 16 stage II, 17 stage III, and seven stage IV tumors, and one with undetermined stage. The carcinomas were all either moderately or poorly differentiated. Thirty cases were conventional adenocarcinoma, not otherwise specified. Other tumor subtypes included seven mucinous (one with and six without signet ring cell component) and four medullary carcinomas. One tumor had combined mucinous and medullary component. Fourteen of 42 tumors (33%) were MSI-H/MMR-D, whereas 28 were MSS. Median follow-up time was 28 months (range, 0-161 months). Seventeen patients died either from the disease or other causes. The patient's demographics and clinicopathologic characteristics are detailed in ❚Table 2❚.
PD-1/PD-L1 Expression
We first analyzed the immune checkpoint receptor (PD-1/PD-L1) expression. PD-L1 could be expressed by tumor cells ❚Image 1A❚ or by peritumoral inflammatory cells, predominantly histiocytes ❚Image 2A❚. Seven of 42 (17%) cases had 1% or more of the tumor cells with membranous PD-L1 expression; IHC scores of 1, 2, and 3 were seen in four, two, and one cases, respectively. Most of the cases (6/7, 86%) had moderate to strong labeling. Eighteen of 42 (43%) tumors showed PD-L1 expressing immune cells in 1% or more of the tumor's cross-sectional area. IHC scores of 1, 2, and 3 were observed in one, 13, and four tumors, respectively. Most of the tumors (16/18, 89%) had moderate to strong membranous staining. All seven cases with 1% or more tumor cells expressing PD-L1 also displayed PD-L1 expression in 1% or more of the tumor's cross-sectional area.
More than half (23/42, 55%) of the tumors showed necrosis (mainly dirty necrosis) at the tumor invasion border, including 13 in 18 (72%) tumors with PD-L1 expression in immune cells and 10 of 24 (42%) without PD-L1 expression. Tumors with necrosis at the invasion front tended to have PD-L1 expression in immune cells (P = .07); however, statistically the difference is not significant. Interestingly, more than 10% of tumor cells in three of four medullary carcinomas and in the medullary component of the combined medullary-mucinous carcinoma expressed PD-L1. In carcinomas of other histologic types, PD-L1 was expressed by abundant histiocytes and some ❚Image 2❚ PD-L1 and PD-1 expression in an adenocarcinoma NOS. A, Abundant histiocytes along the tumor glands strongly express PD-L1 (×100). B, Most peritumoral and intratumoral lymphocytes strongly express PD-1 (×200).
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Thota et al / PD-1 as a TargeT in small Bowel CanCer observed in six of 28 (21%, P < .01), which is consistent with the data from colorectal cancers. 7 Two MSI-H/ MMR-D tumors with no PD-L1 expression were mucinous adenocarcinoma. Interestingly, all seven mucinous carcinomas in this study had negative PD-L1 expression. The mucinous component of the combined medullary-mucinous carcinoma also did not express PD-L1. As expected, most PD-L1-expressing tumors had some pathologic features of MSI-H/MMR-D tumor, including Crohn disease-like lymphoid reaction, intratumoral lymphocytic infiltration, and pushing borders. 
Tumor Immune Microenvironment
We also analyzed peritumoral lymphocytic infiltration in PD-L1-positive tumors and PD-L1-negative tumors ❚Figure 1❚. Significantly more T lymphocytes (CD3+ cells) were found in PD-L1-positive tumors compared to PD-L1-negative tumors (969 ± 72/2 hpf vs 527 ± 48/2 hpf, P < .01). In addition, PD-L1-expressing tumors contained more CD4+ (522 ± 51/2 hpf vs 331 ± 36/2 hpf, P < .01) and CD8+ (466 ± 43/2 hpf vs 186 ± 23/2 hpf, P < .01) T cells than those without expression of PD-L1. The ratio of CD4+/CD8+ cells was lower in the PD-L1-positive group than the PD-L1-negative group (1.2 ± 0.1 vs 2.2 ± 0.3, P = .02). In all tumors, there were fewer CD20+ B cells than CD3+ T cells. CD20+ B cells were mainly present in peritumoral lymphoid aggregates.
When the tumors were divided into group 1 with PD-1 IHC score ranging from 0 to 50, and group 2 with PD-1 IHC score higher than 50, significantly more CD3+ cells were in group 2 compared to group 1 (580 ± 55 vs 823 ± 90/2 hpf, P = .02).
Discussion
In this study, we analyzed the immune microenvironment of small intestinal adenocarcinomas to explore the potential role of immune checkpoint blockade in these rare tumors. This is the first study to demonstrate an activated PD-1 pathway with high expression of immune inhibitory signals in small intestinal adenocarcinomas. PD-1 and PD-L1 expression was noted in 83% and 43% of all tumors, respectively. PD-L1-positive tumors had prominent intratumoral and peritumoral T-lymphocytic infiltration, which suggests a potentially immune-evasive microenvironment in small bowel tumors.
The expression of PD-L1 by tumor cells and immune infiltrates was significantly associated with high expression of PD-1 on the tumor-infiltrating lymphocytes. Similar results were reported by Taube et al in a study of 41 patients with advanced solid tumors treated with anti PD-1 therapy.
3 PD-L1 expression on tumor cells has been known to predict responses to PD-1/PD-L1 blockade therapy. 3 In the initial phase I study of anti-PD-1 therapy in advanced solid tumors by Topalian et al, the PD-L1 positive tumors had higher response rates than PD-L1-negative tumors (36% vs 0%; P = .006). Interestingly, no clinical activity was noted in colorectal tumors. 4 Unselected metastatic colon cancers in general have been refractory to PD-1/PD-L1 therapy. 10, 11 However, in a recent phase II study of PD-1 blockade in mismatch repair deficient tumors by Le et al, the MSI-H colorectal tumors had high objective response rates (40% vs 0%) and better progression-free survival (78% vs 11%) compared to MSS tumors. 5 Therefore, mismatch repair status seems to predict the benefit for immune checkpoint blockade in colorectal cancer. In an effort to better understand the benefit of immune blockade therapy in colorectal cancers, a detailed evaluation of its tumor immune microenvironment was undertaken by Llosa et al. They found a selective high expression of PD-1 and PD-L1 in MSI-H colon tumors. 7 Based on these findings, currently there are several ongoing phase II/III clinical trials evaluating the role of immune therapy in MSI-H colon tumors (NCT02460198, NCT02563002, NCT02227667). The National Comprehensive Cancer Network guidelines recommend treating small intestinal adenocarcinomas similar to large bowel tumors. 12 Nevertheless, these two tumor types have considerable differences in tumor characteristics and prognosis. The basic immune and molecular biology of these tumors is likely different. For example, it is believed that relatively there are more MSI-H tumors in the small intestine than in the colorectum. In fact, a third (14/42) of the cases in our study were MSI-H. In addition, we found that the vast majority of MSI-H small intestinal adenocarcinomas had high expression of PD-1 and PD-L1, suggesting patients with small intestinal adenocarcinoma may benefit more from the immune checkpoint blockade than those with colorectal cancer.
The presence of high tumor-infiltrating cytotoxic T lymphocytes especially along the invasive front of the tumor is considered a manifestation of the host immune escape mechanism, which predicts response to anti PD-1/ PD-L1 therapy. 13 Therefore, in order to evaluate the immunological context of PD-L1 expression, we analyzed its correlations with peritumoral T cells by IHClabeling the tumor sections with CD3, CD4, and CD8. Similar to what has been seen in other immune-responsive tumors such as melanoma and MSI-H colon cancer, the immune microenvironment of PD-L1-expressing small intestinal adenocarcinomas showed strong T-lymphocytic infiltration along with prominent histiocytes. 7, 13 In MSS colorectal cancers, high numbers of tumor stromal CD3+ cells were also associated with a response to active specific immunotherapy.
14 Although at a lower frequency, we found approximately 20% of MSS tumors showed PD-L1 expression. These tumors also contained similar numbers of peritumoral CD3+ cells to MSI-H/MMR-D tumors. Therefore, immune microenvironments of MSS and MSI-H/MMR-D PD-L1-expressing tumors are very similar.
PD-1-expressing tumors had more CD3-positive cells while PD-L1-expressing tumors had more CD4+ and CD8+ T cells, but a lower CD4/CD8 ratio compared to PD-L1-negative tumors. Theoretically, such a CD8+ (cytotoxic) T cell-rich microenvironment could naturally work to eliminate the tumors. Mechanisms underlying tumor growth under this immune microenvironment is unknown. It has been suggested that upregulated expression of multiple immune checkpoints including the PD-1/ PD-L1 pathway counterbalances the immune microenvironment. 7 Therefore, inhibition of the PD-1/PD-L1 pathway could enhance the anti-tumor immune response achieved by the existing cytotoxic T cells, thereby effectively treating these cancers.
In summary, PD-1 and PD-L1 are highly expressed by inflammatory cells (mainly histiocytes) and tumor cells in small intestinal adenocarcinoma. MSI-H/MMR-D tumors are more likely to express PD-L1. High PD-1 expression on the infiltrating lymphocytes is associated with high PD-L1 expression. Along with high PD-1/ PD-L1 expression, the small intestinal adenocarcinomas had a T-lymphocyte-rich immune microenvironment. Thus, our data provide a rationale for developing a novel therapy of immune checkpoint blockade in small bowel tumors. Indeed, based on these findings, we are initiating a phase II clinical trial of the monoclonal anti-PD-L1 antibody avelumab in patients with advanced small bowel adenocarcinoma.
